Latest filing published 02 Jan 2026 for Janux Therapeutics, Inc., €22k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andrew Hollman Meyer discloses dealings in Janux Therapeutics, Inc. to SEC (Form 4). The record holds 11 filings, for trades running from 27 September 2024 to 2 January 2026.
The open-market record consists of 1 sale worth €22k, with no purchase. The rest of the record consists of 1 share grant and 9 option exercises. Since January 2026: no purchases and 1 sale on the market.
On 2 January 2026 came the latest disclosure, an open-market sale for €22k in Janux Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations